<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053038</url>
  </required_header>
  <id_info>
    <org_study_id>13SM1797</org_study_id>
    <nct_id>NCT02053038</nct_id>
  </id_info>
  <brief_title>Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation</brief_title>
  <acronym>DEFINE-FLAIR</acronym>
  <official_title>Prospective, Multi-center, Double Blind, Randomised Study to Test the Safety of Deferral of Stenting in Physiological Non-significant Lesions in a Clinical Population of Intermediate Stenoses Using iFR and FFR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Narrowing of coronary arteries interferes with blood flow and can cause chest pain. But&#xD;
      patients may have more than one narrowing and studies have shown that not all narrowings need&#xD;
      to be treated. To identify the narrowings that need treating cardiologists sometimes quantify&#xD;
      the extent of the narrowing by measuring fractional flow reserve (FFR, the ratio of the&#xD;
      pressure in the aorta to the pressure downstream of the narrowing).This technique requires&#xD;
      the administration of drugs that add cost and time to the procedure and in some countries are&#xD;
      simply unavailable. As a result despite the clear health and healthcare costs benefits of FFR&#xD;
      its use is limited to less than 5% of procedure. We have developed a new technique called the&#xD;
      instantaneous wave-free ratio (iFR) that does not require the administration of drugs for its&#xD;
      accurate assessment. It has been approved for use in this indication. This study aims to&#xD;
      compare clinical outcomes of patients whose treatment has been guided by iFR to those whose&#xD;
      treatment has been guided by FFR. If iFR is found to provide the same clinical outcomes as&#xD;
      FFR its adoption will permit the clear benefits of this approach of identifying the coronary&#xD;
      narrowings that really need treatment to be applicable to a much larger patient population&#xD;
      and further improve healthcare costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      Patients with one or more coronary stenoses, in which the physiological severity from&#xD;
      coronary angiography is in question, will be randomised 1:1 to use of the instantaneous wave&#xD;
      free ratio (iFR) or fractional flow reserve (FFR) to guide the treatment strategy for&#xD;
      percutaneous coronary intervention (PCI).&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      To assess whether the iFR is non-inferior to FFR when used to guide treatment of coronary&#xD;
      stenosis with PCI.&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      The primary endpoint will be major adverse cardiac event rate in the iFR and FFR groups at 30&#xD;
      days, 1, 2, and 5 years.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      This will be an international multi-centre study of 2500 patients. From population estimates,&#xD;
      35% of the total study population will present with stable angina and 65% will have acute&#xD;
      coronary syndrome.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients will be eligible when the physiological severity of a stenosis within a vessel is in&#xD;
      question. In the cases of stable angina this will be confined to the target vessel, or with&#xD;
      acute coronary syndrome assessment this will be made in the non-culprit vessel.&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      Anticipated recruitment is 12 months. Follow-up will be performed at 30 days, 1, 2 and 5&#xD;
      years.&#xD;
&#xD;
      Results:&#xD;
&#xD;
      Primary outcome results will be reported in Spring 2017.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">January 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>Composite of death, myocardial infarction, unplanned revascularisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death (all cause)</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (cardiovascular)</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat revascularisation</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost associated to iFR or FFR measurement</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>Cost associated to iFR or FFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EQ-5D-5L and Seattle Angina Questionnaire</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost savings of removing secondary investigations</measure>
    <time_frame>30 days, 1, 2 and 5 years</time_frame>
    <description>7) Cost savings of removing secondary investigations, by assessing/treating non-culprit acute coronary syndrome (ACS) at the time of index presentation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>iFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment guided by iFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment guided by FFR</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iFR</intervention_name>
    <description>Treatment guided by instantaneous wave-free ratio</description>
    <arm_group_label>iFR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFR</intervention_name>
    <description>Treatment guided by Fractional Flow Reserve</description>
    <arm_group_label>FFR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years of age&#xD;
&#xD;
          2. Willing to participate and able to understand, read and sign the informed consent&#xD;
             document before the planned procedure&#xD;
&#xD;
          3. Eligible for coronary angiography and/or percutaneous coronary intervention&#xD;
&#xD;
          4. Coronary artery disease with at least 1 or more native major epicardial vessels or&#xD;
             their branches by coronary angiogram with visually assessed de novo coronary stenosis&#xD;
             in which the physiological severity of the lesion is in question (typically 40-70%&#xD;
             diameter stenosis).&#xD;
&#xD;
          5. Stable angina or acute coronary syndrome (non-culprit vessels only and outside of&#xD;
             primary intervention during acute STEMI)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel&#xD;
&#xD;
          2. Significant left main stenosis (&gt;50% narrowing)&#xD;
&#xD;
          3. Tandem stenoses separated by more than 10 mm that require separate pressure guide wire&#xD;
             interrogation or percutaneous coronary intervention (PCI) (not to be interrogated or&#xD;
             treated as a single stenosis)&#xD;
&#xD;
          4. Total coronary occlusions (CTOs). NOTE: Patients with CTOs can be included if i)&#xD;
             treatment of the CTO is completed first, ii) the CTO PCI is successful, iii) the CTO&#xD;
             PCI is successful and iii) the physiological lesion is in another vessel&#xD;
&#xD;
          5. Restenotic lesions&#xD;
&#xD;
          6. Hemodynamic instability at the time of intervention (heart rate&lt;50 beats per minute,&#xD;
             systolic blood pressure &lt;90mmHg), balloon pump&#xD;
&#xD;
          7. Significant contraindication to adenosine administration (e.g. heart block, severe&#xD;
             asthma)&#xD;
&#xD;
          8. Contraindications to PCI (percutaneous coronary intervention) or drug-eluting stent&#xD;
             (DES) implantation&#xD;
&#xD;
          9. Heavily calcified or tortuous vessels&#xD;
&#xD;
         10. Significant hepatic or lung disease (chronic pulmonary obstructive disease), and/or&#xD;
             malignant disease with unfavourable prognosis that may influence survival within the&#xD;
             next 5 years&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. STEMI (ST elevation myocardial infarction) within 48 hours of procedure&#xD;
&#xD;
         13. Severe valvular heart disease&#xD;
&#xD;
         14. ACS patients in whom more than one target vessel is present&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin ER Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Escaned, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Serruys, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manesh Patel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sayan Sen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arnold Seto</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Altman</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Habib Samady</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allen Jeremias</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manesh Patel</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sam Lehman</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darren Walters</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Sapontis</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ravinay Bhindi</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Vrints</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luc Janssens</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahmed Khashaba</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mika Laine</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florian Krackhardt</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olaf Going</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldemar Bojara</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tobias Haerle</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciro Indolfi</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giampaolo Nicolli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flavio Ribichini</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroaki Takashima</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroyoshi Yokoi</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuetsu Kikuta</name>
      <address>
        <city>Fukuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hitosh Matsuo</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nob Tanaka</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Wook Nam</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joon-Hyung Doh</name>
      <address>
        <city>Daehwa</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon-Kwon Koo</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eun-Seok Shin</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrejs Erglis</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Piek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niels Van Royen</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martijn Meuwissen</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugo Vinhas</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sergio Baptista</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedro Canas Silva</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ali Alghamadi</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farrel Hellig</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salvatore Brugaletta</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eduardo Alegria</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murat Sezer</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kare Tang</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suneel Talwar</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Sharp</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ranil De Silva</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajesh Kharbanda</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Gerber</name>
      <address>
        <city>St Leonards</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

